Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics

[1]  F. Hamdy,et al.  Feasibility and safety of radical prostatectomy for oligo‐metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligo‐Metastases to the bone (TRoMbone) trial , 2022 .

[2]  A. Choudhury.  PTEN‐PI3K pathway alterations in advanced prostate cancer and clinical implications , 2022, The Prostate.

[3]  M. Morris,et al.  Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Haas,et al.  Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Carles,et al.  Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design , 2022, The Lancet.

[6]  I. Gill,et al.  Trends in Incidence of Metastatic Prostate Cancer in the US , 2022, JAMA network open.

[7]  T. Jang,et al.  Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy , 2022, Prostate international.

[8]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[9]  M. Cooperberg,et al.  Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. , 2021, JAMA oncology.

[10]  N. Tomiyama,et al.  Whole-body MRI: detecting bone metastases from prostate cancer , 2021, Japanese Journal of Radiology.

[11]  H. Olsson,et al.  Mortality in men with castration‐resistant prostate cancer—A long‐term follow‐up of a population‐based real‐world cohort , 2021, BJUI compass.

[12]  Kirsten L. Greene,et al.  Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging , 2021, The Journal of Nuclear Medicine.

[13]  J. Osborne,et al.  Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice. , 2021, Clinical imaging.

[14]  F. Saad,et al.  Treatment and trials in non-metastatic castration-resistant prostate cancer , 2021, Nature Reviews Urology.

[15]  F. Saad,et al.  Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. , 2021, European urology focus.

[16]  T. Daskivich,et al.  Next-generation imaging in localized high-risk prostate cancer , 2021, Prostate Cancer and Prostatic Diseases.

[17]  A. Wyatt,et al.  Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer , 2021, Nature Reviews Urology.

[18]  Yin Zhang,et al.  Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis , 2021, Frontiers in Oncology.

[19]  P. Caroli,et al.  Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging , 2021, Therapeutic advances in medical oncology.

[20]  I. Padjen,et al.  The analysis of waiting time and utilization of computed tomography and magnetic resonance imaging in Croatia: a nationwide survey , 2020, Croatian Medical Journal.

[21]  P. Summers,et al.  Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels , 2020, Cancer Imaging.

[22]  C. Liang,et al.  Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review , 2020, Frontiers in Oncology.

[23]  W. Lowrance,et al.  Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. , 2020, The Journal of urology.

[24]  Robin L. Jones,et al.  611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) , 2020 .

[25]  Anne E. Calvaresi,et al.  Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Lowrance,et al.  18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. , 2020, Urologic oncology.

[27]  A. Afshar-Oromieh,et al.  Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy , 2020, EJNMMI Research.

[28]  Ken R. Smith,et al.  Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Lawrentschuk,et al.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study , 2020, The Lancet.

[30]  N. Lawrentschuk,et al.  The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer , 2020, BJU international.

[31]  S. W. Lee,et al.  The role of 18F-fluciclovine PET in the management of prostate cancer: a systematic review and meta-analysis. , 2019, Clinical radiology.

[32]  R. Cress,et al.  Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. , 2019, European urology focus.

[33]  A. Bardelli,et al.  How liquid biopsies can change clinical practice in oncology. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Sydes,et al.  Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  E. Antonarakis,et al.  Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. , 2019, Clinical genitourinary cancer.

[36]  A. Villers,et al.  ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  J. Eastham,et al.  Current Status of MRI and PET in the NCCN Guidelines for Prostate Cancer. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[38]  D. Ye,et al.  Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. , 2019, The Lancet. Oncology.

[39]  E. Schaeffer,et al.  Germline and Somatic Mutations in Prostate Cancer for the Clinician. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

[40]  Prashanth Rawla,et al.  Epidemiology of Prostate Cancer , 2019, World journal of oncology.

[41]  A. Zwinderman,et al.  Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. , 2019, European urology.

[42]  P. Carroll,et al.  Impact of Staging 68Ga-PSMA-11 PET Scans on Radiation Treatment Plansin Patients With Prostate Cancer. , 2019, Urology.

[43]  M. Parmar,et al.  Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial , 2018, The Lancet.

[44]  I. Faraoni,et al.  Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors , 2018, Cancers.

[45]  T. Ahlering,et al.  Results of Phase 1 study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer , 2018, Prostate international.

[46]  J. Phillips,et al.  Prostate Cancer Screening Trends After United States Preventative Services Task Force Guidelines in an Underserved Population , 2018, Health equity.

[47]  F. Montorsi,et al.  Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. , 2018, European urology oncology.

[48]  N. Kyprianou,et al.  Profiling Prostate Cancer Therapeutic Resistance , 2018, International journal of molecular sciences.

[49]  T. Ahlering,et al.  Unintended consequences of decreased PSA-based prostate cancer screening , 2018, World Journal of Urology.

[50]  David F Jarrard,et al.  Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Z. Szallasi,et al.  The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer , 2017, Cancer.

[52]  N. Sharifi,et al.  Androgen Signaling in Prostate Cancer. , 2017, Cold Spring Harbor perspectives in medicine.

[53]  Evis Sala,et al.  METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer☆ , 2017, European urology.

[54]  Damien Bolton,et al.  Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. , 2016, European urology.

[55]  J. Eshleman,et al.  Clinical mutational profiling of bone metastases of lung and colon carcinoma and malignant melanoma using next‐generation sequencing , 2016, Cancer cytopathology.

[56]  P. Nelson,et al.  Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer. , 2016, European urology.

[57]  R. Laing,et al.  Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial , 2016, The Lancet.

[58]  R. Eeles,et al.  Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. , 2015, European urology.

[59]  J. Palvimo,et al.  Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies , 2015, Scientific Reports.

[60]  I. Thompson,et al.  SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  F. Saad,et al.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. , 2015, The Lancet. Oncology.

[62]  G. Sonpavde,et al.  The hypothalamic–pituitary–gonadal axis and prostate cancer: implications for androgen deprivation therapy , 2014, World Journal of Urology.

[63]  Z. Jia,et al.  Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis , 2014, Skeletal Radiology.

[64]  A. Ravaud,et al.  Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. , 2013, The Lancet. Oncology.

[65]  F. Saad,et al.  Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. , 2012, The Lancet. Oncology.

[66]  Laurence Collette,et al.  Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.

[67]  R. Eeles,et al.  The role of BRCA1 and BRCA2 in prostate cancer. , 2012, Asian journal of andrology.

[68]  W. Leslie,et al.  A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy. , 2011, Current oncology.

[69]  Lorenzo Marconi,et al.  EAU guidelines on renal cell carcinoma: 2014 update. , 2010, European urology.

[70]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  S. Fanti,et al.  11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy. , 2006, The Journal of urology.

[72]  M. Rowlands,et al.  Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. , 1995, Journal of medicinal chemistry.

[73]  M. Javadi,et al.  18F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: a meta-analysis of diagnostic accuracy studies , 2019, Annals of Nuclear Medicine.

[74]  S. Verma,et al.  Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology. , 2016, European journal of radiology.

[75]  M. Soloway,et al.  Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan , 1988, Cancer.